EyePoint Pharmaceuticals is a pharmaceutical company focused on developing and commercializing ophthalmic products for the treatment of eye diseases. Co.'s primary product candidate, EYP-1901, is a potential sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg for intravitreal injection, is for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. DEXYCU® (dexamethasone intraocular suspension) 9%, for intraocular administration, is for the treatment of post-operative ocular inflammation. The EYPT stock yearly return is shown above.
The yearly return on the EYPT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2016 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the EYPT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|